Lanthanum carbonate - A first line phosphate binder?

Seminars in Dialysis

Volumn 20, Issue 4, 2007, Pages 325-328

  De Freitas, Declan ^a   Donne, Rosemary L ^a   Hutchison, Alastair J ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; LANTHANUM; LANTHANUM CARBONATE;

ARTICLE; BIOAVAILABILITY; CHEMISTRY; CHRONIC KIDNEY FAILURE; DISORDERS OF MINERAL, ELECTROLYTE AND METAL METABOLISM; HUMAN; METABOLISM; ORAL DRUG ADMINISTRATION; RENAL REPLACEMENT THERAPY;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; CHELATING AGENTS; HUMANS; KIDNEY FAILURE, CHRONIC; LANTHANUM; PHOSPHORUS METABOLISM DISORDERS; RENAL DIALYSIS;

EID: 34547161837     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2007.00301.x     Document Type: Article

References (27)

1. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM : Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15 : 2208 2218, 2004
2. Lowrie EG, Lew NL : Death risk in haemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15 : 458 482, 1990
3. Delmez J, Slatopolsky E : Hyperphosphataemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 4 : 303 317, 1992
4. Rufino M, de Bonis E, Martin M, Rebollo S, Martin B, Miquel R, Cobo M, Hernandez D, Torres A, Lorenzo V : Is it possible to control hyperphosphataemia with diet, without inducing protein malnutrition? Nephrol Dial Transplant 13 (Suppl. 3 65 67, 1998
5. Lorenzo V, Torres A : Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly. Drugs Aging 21 : 153 165, 2004
6. King RO, Fricker SP : Rare earth phosphate binders. JMPC Monthly Report (March) 1997
7. Drueke TB : Risks related to metal absorption. Proceedings of a roundtable meeting held at the ASN/ISN World Nephrology Convention. Nephrol Dial Transplant 17 (Suppl 2): 1, 2002
8. Pennick M, Dennis K, Damment SJ : Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. J Clin Pharmacol 46 : 738 746, 2006
9. Xu J, Ling E-A : Studies of the ultrastructure and permeability of the blood-brain barrier in the developing corpus collosum in postnatal rat brain using electron dense tracers. J Anat 184 : 227 237, 1994
10. Hutchison AJ : Lanthanum carbonate: a novel non-calcaemic phosphate binder in dialysis patients. Nephrol Dial Transplant 15 : 113, 2000
11. Joy MS, Finn WF, LAM-302 Study Group : Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 42 : 96 107, 2003
12. Hutchison AJ : Improving phosphate-binder therapy as a way forward. Nephrol Dial Transplant 19 Suppl. 1 i19 i24, 2004
13. Hutchison AJ, Speake M, Albaaj F : Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol Dial Transplant 19 : 1902 1906, 2004
14. Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, Backs W, Jamar R, Vosskuhler A : Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 100 : c8 c19, 2005
15. Lacour B, Lucas A, Auchere D, Ruellan N, de Serre Patey NM, Drueke TB : Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 67 : 1062 1069, 2005
16. Slatopolsky E, Liapis H, Finch J : Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int 68 : 2809 2813, 2005
17. Persy VP, Behets GJ, Bervoets AR, De Broe ME, D'Haese PC : Lanthanum: a safe phosphate binder. Semin Dial 19 : 195 199, 2006
18. Finn WF, Joy MS, LAM-308 Study Group : A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis. Curr Med Res Opin 21 : 657 664, 2005
19. Finn WF, SPD 405-307 Lanthanum Study Group : Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 65 : 191 202, 2006
20. Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, Backs W, Jamar R, Vosskuhler A : Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract 102 : c61 c71, 2006
21. Hutchison AJ, SPD405-301 study group : Long-term safety, efficacy and tolerability of lanthanum carbonate: results from a 3.5 year study (abstract). Nephrol Dial Transplant 20 (Suppl. 5 5, 2005
22. Pratt R : Evidence for the long-term safety and tolerability of lanthanum carbonate. J Am Soc Nephrol 16 : 765A, 2005
23. U.S. Renal Data System, USRDS 2005 Annual Data Report : Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2005
24. D'Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G, Sulowicz W, Ferreira A, Torres A, Curic S, Popovic M, Dimkovic N, De Broe ME : A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int (Suppl.) 85 : S73 S78, 2003
25. Freemont AJ, Hoyland JA, Denton J, Lanthanum Carbonate SPD405-303 Study Group : The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin Nephrol 64 : 428 437, 2005
26. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P : Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68 : 1815 1824, 2005
27. National Institute for Health and Clinical Excellence : Appraisal of Cinacalcet hydrochloride for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy. http://guidance.nice.org.uk/TA117/guidance/pdf/English,accessed May14,2007.